Over the last five years, there has been a dramatic increase in the global development of transformative gene therapies. Given this increase and the global development, there is a clear need for harmonization across global regulatory authorities to ensure that these therapies can be delivered to the patients that need them as quickly as possible. Such harmonization efforts may include regulatory terminology and definitions, and nonclinical, quality, and clinical considerations.
